Nearly 25 years after the first FDA-approved antibody-drug conjugate (ADC), the field of antibody therapeutics continues to evolve. Advances in antibody development and engineering, as well as transformative progress in our understanding of biological processes and disease etiology, have unlocked new possibilities. This, in turn, has fueled an ...
read more